RIGL Q4 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M+21.2% YoY

Gross Profit

$64M91.5% margin

Operating Income

$23M33.2% margin

Net Income

$268M384.0% margin

EPS (Diluted)

$14.11

QoQ Revenue Growth

+0.5%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$514M

Total Liabilities

$122M

Stockholders' Equity

$391M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$58M	+21.2%
Gross Profit	$64M	$52M	+23.2%
Operating Income	$23M	$17M	+39.1%
Net Income	$268M	$14M	+1769.2%

Revenue Segments

Contract revenues from collaborations

$4M100%